Kearsley-Fleet L, et al. - In children with juvenile idiopathic arthritis (JIA), authors characterized rituximab (RTX) use and outcomes. They included all JIA patients within the UK Biologics for Children with Rheumatic Diseases study starting RTX and assessed disease activity at RTX start and at follow-up. The probable effectiveness of RTX as a treatment option for children who do not respond to TNF inhibitor, was seen in this real-world cohort of children with JIA, the majority with polyarticular or extended oligoarticular JIA. A low rate of serious infections was also reported with RTX treatment. More than one course of RTX was reported by more than half of the children involved. A total of 219 days was the median time between each course. During follow-up, 41% of patients reported switching to another biologic, including tocilizumab, abatacept, and TNF inhibitors.